Evidence map›Paper›PMID 26486699›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016

Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight.

Meghna Desai, Julie Gutman, Steve M Taylor, Ryan E Wiegand, Carole Khairallah, Kassoum Kayentao, Peter Ouma, Sheick O Coulibaly, Linda Kalilani, Kimberly E Mace and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05757167 (Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity), which is not on this map. Cited by 111 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05757167 phase4active not recruitingnot on this mapstarted 2023, after this paper: background citation

Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity

TypeinterventionalSponsorDuke UniversityRan2023 to 2026Enrolled2,174ConditionsMalaria,Falciparum, Malaria in Pregnancy, Malaria in Childbirth, PregnancyArmsMalaria High-Sensitivity Rapid Diagnostic Test (HS-RDT), Artemether-lumefantrine (AL)
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Meghna DesaiMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Julie GutmanMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Steve M TaylorDivision of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina.
Ryan E WiegandMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Carole KhairallahDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, United Kingdom.
Kassoum KayentaoDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, United Kingdom.
Peter OumaMalaria Branch, Center for Global Health Research, Kenya Medical Research Institute, Kisumu.
Sheick O CoulibalyUniversity of Ouagadougou, Burkina Faso.
Linda KalilaniCollege of Medicine, University of Malawi, Blantyre.
Kimberly E MaceMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Emmanuel ArinaitweInfectious Disease Research Collaboration, Kampala, Uganda.
Don P MathangaCollege of Medicine, University of Malawi, Blantyre.
Ogobara DoumboMalaria Research and Training Center, University of Sciences, Technics and Technologies of Bamako, Mali.
Kephas OtienoMalaria Branch, Center for Global Health Research, Kenya Medical Research Institute, Kisumu.
Dabira EdgarUniversity of Ouagadougou, Burkina Faso.
Ebbie ChalulukaCollege of Medicine, University of Malawi, Blantyre.
Mulakwa KamuliwoNational Malaria Control Center, Lusaka, Zambia.
Veronica AdesNew York University Langone Medical Center, New York.
Jacek SkarbinskiMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Ya Ping ShiMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Pascal MagnussenCentre for Medical Parasitology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Steve MeshnickDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
Feiko O Ter KuileDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, United Kingdom.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundOwing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial.

methodsBetween 2009 and 2013, both the efficacy of IPTp-SP at clearing existing peripheral malaria infections and the effectiveness of IPTp-SP at reducing low birth weight (LBW) were assessed among human immunodeficiency virus-uninfected participants in 8 sites in 6 countries. Sites were classified as high, medium, or low resistance after measuring parasite mutations conferring SP resistance. An individual-level prospective pooled analysis was conducted.

resultsAmong 1222 parasitemic pregnant women, overall polymerase chain reaction-uncorrected and -corrected failure rates by day 42 were 21.3% and 10.0%, respectively (39.7% and 21.1% in high-resistance areas; 4.9% and 1.1% in low-resistance areas). Median time to recurrence decreased with increasing prevalence of Pfdhps-K540E. Among 6099 women at delivery, IPTp-SP was associated with a 22% reduction in the risk of LBW (prevalence ratio [PR], 0.78; 95% confidence interval [CI], .69-.88; P < .001). This association was not modified by insecticide-treated net use or gravidity, and remained significant in areas with high SP resistance (PR, 0.81; 95% CI, .67-.97; P = .02).

conclusionsThe efficacy of SP to clear peripheral parasites and prevent new infections during pregnancy is compromised in areas with >90% prevalence of Pfdhps-K540E. Nevertheless, in these high-resistance areas, IPTp-SP use remains associated with increases in birth weight and maternal hemoglobin. The effectiveness of IPTp in eastern and southern Africa is threatened by further increases in SP resistance and reinforces the need to evaluate alternative drugs and strategies for the control of malaria in pregnancy.

Indexed as

Drug ResistanceInfant, Low Birth WeightAdultAfrica South of the SaharaAmino Acid SubstitutionAntimalarialsDihydropteroate SynthaseDrug CombinationsDrug TherapyFemaleHumansInfant, NewbornMalariaMutant ProteinsPlasmodium falciparumPregnancyAntimalarialsDihydropteroate SynthaseDrug Combinationsfanasil, pyrimethamine drug combinationMutant ProteinsPyrimethamineSulfadoxineeffectivenessintermittent preventive treatmentmalaria in pregnancysulfadoxine-pyrimethamine resistance

Identifiers

PMID26486699
PMCPMC4762476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.